TY - JOUR
T1 - Machine learning analyses of highly-multiplexed immunofluorescence identifies distinct tumor and stromal cell populations in primary pancreatic tumors
AU - Vance, Krysten
AU - Alitinok, Alphan
AU - Winfree, Seth
AU - Jensen-Smith, Heather
AU - Swanson, Benjamin J.
AU - Grandgenet, Paul M.
AU - Klute, Kelsey A.
AU - Crichton, Daniel J.
AU - Hollingsworth, Michael A.
N1 - Funding Information:
All samples collected were from consented patients through the University of Nebraska Medical Center Rapid Autopsy Program (supported by P50CA127297, U01CA210240, P30CA36727, and R50CA211462). We would like to thank UNMCs tissue science facilities for sample preparation, the patients and family members who agreed to participate in our RAP program, and the RAP volunteers who provided countless hours of work collecting these tissues.
Publisher Copyright:
© 2022 - IOS Press. All rights reserved.
PY - 2022
Y1 - 2022
N2 - Background: Pancreatic ductal adenocarcinoma (PDAC) is a formidable challenge for patients and clinicians. Objective: To analyze the distribution of 31 different markers in tumor and stromal portions of the tumor microenvironment (TME) and identify immune cell populations to better understand how neoplastic, non-malignant structural, and immune cells, diversify the TME and influence PDAC progression. METHODS: Whole slide imaging (WSI) and cyclic multiplexed-immunofluorescence (MxIF) was used to collect 31 different markers over the course of nine distinctive imaging series of human PDAC samples. Image registration and machine learning algorithms were developed to largely automate an imaging analysis pipeline identifying distinct cell types in the TME. Results: A random forest algorithm accurately predicted tumor and stromal-rich areas with 87% accuracy using 31 markers and 77% accuracy using only five markers. Top tumor-predictive markers guided downstream analyses to identify immune populations effectively invading into the tumor, including dendritic cells, CD4+ T cells, and multiple immunoregulatory subtypes. Conclusions: Immunoprofiling of PDAC to identify differential distribution of immune cells in the TME is critical for understanding disease progression, response and/or resistance to treatment, and the development of new treatment strategies.
AB - Background: Pancreatic ductal adenocarcinoma (PDAC) is a formidable challenge for patients and clinicians. Objective: To analyze the distribution of 31 different markers in tumor and stromal portions of the tumor microenvironment (TME) and identify immune cell populations to better understand how neoplastic, non-malignant structural, and immune cells, diversify the TME and influence PDAC progression. METHODS: Whole slide imaging (WSI) and cyclic multiplexed-immunofluorescence (MxIF) was used to collect 31 different markers over the course of nine distinctive imaging series of human PDAC samples. Image registration and machine learning algorithms were developed to largely automate an imaging analysis pipeline identifying distinct cell types in the TME. Results: A random forest algorithm accurately predicted tumor and stromal-rich areas with 87% accuracy using 31 markers and 77% accuracy using only five markers. Top tumor-predictive markers guided downstream analyses to identify immune populations effectively invading into the tumor, including dendritic cells, CD4+ T cells, and multiple immunoregulatory subtypes. Conclusions: Immunoprofiling of PDAC to identify differential distribution of immune cells in the TME is critical for understanding disease progression, response and/or resistance to treatment, and the development of new treatment strategies.
KW - Pancreatic ductal adenocarcinoma (PDAC)
KW - Whole Slide Imaging (WSI)
KW - machine-learning
KW - multiplexed-immunofluorescence (MxIF)
KW - tumor microenvironment (TME)
UR - http://www.scopus.com/inward/record.url?scp=85125549682&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125549682&partnerID=8YFLogxK
U2 - 10.3233/CBM-210308
DO - 10.3233/CBM-210308
M3 - Article
C2 - 35213363
AN - SCOPUS:85125549682
SN - 1574-0153
VL - 33
SP - 219
EP - 235
JO - Cancer Biomarkers
JF - Cancer Biomarkers
IS - 2
ER -